Known inhibitors of gluconeogenesis, metformin (a first-line treatment for type 2 diabetes), insulin, and AICAR (5-aminoimidazole-4-carboxamide riboside) as an AMPK activator inhibiting transcription of the gluconeogenesis genes, were used as the experimental control. This evidence concerns the gene INS and type 2 diabetes mellitus.